source
- Nouscom secures $135 million Series D to advance lead cancer vaccine into Phase 2Clinical-stage biotech Nouscom announced it has closed a $135 million Series D financing round that was oversubscribed. The capital will be used to move its lead cancer vaccine candidate into a Pha…
- Merck/Moderna vaccine and Summit/Akeso bispecific therapy among key highlights at ESMO 2026The European Society of Medical Oncology (ESMO) meeting in Madrid this weekend will showcase several high‑profile oncology programs. Among the most watched are Merck and Moderna’s personalized can…